Heumann, Thatcher R.
Baretti, Marina
Sugar, Elizabeth A.
Durham, Jennifer N.
Linden, Sheila
Lopez-Vidal, Tamara Y.
Leatherman, James
Cope, Leslie
Sharma, Anup
Weekes, Colin D.
O’Dwyer, Peter J.
Reiss, Kim A.
Monga, Dulabh K.
Ahuja, Nita
Azad, Nilofer S.
Funding for this research was provided by:
Gateway Foundation (121785)
Article History
Received: 22 July 2022
Accepted: 11 October 2022
First Online: 3 December 2022
Declarations
:
: The study protocol was reviewed and approved by the institutional review board of the Johns Hopkins School of Medicine and the FDA. The study was conducted according to the Declaration of Helsinki and the guidelines for Good Clinical Practice. All patients provided written informed consent before the conduct of any study procedures and after a full explanation of the study to the patient by the study investigator.
: Not applicable.
: N. A. receives research funding from BMS, Merck, Incyte, Syndax, Intensity, Bayer, EMD Serono. She receives financial compensation as a consultant for AstraZeneca and Merck/EMD Serono. P. O. receives research support from Pfizer, Genentech, BMS, AZ, GSK, Five Prime, FortySeven, Merck, Syndax, BBI, Novartis, Celgene, Incyte, Lilly/Imclone, array, h3biomedicine, Taiho, Minneamrata, pharmacyclics/abbvie, Mirati. He also provides expert testimony for Lilly, Dai-ichi Sankyo. N. A. has received grant funding from Cepheid and Astex and has served as consultant to Ethicon. She has licensed methylation biomarkers to Cepheid. No potential conflicts of interest were disclosed by the other authors.